--- title: "Ernexa Therapeutics (ERNA) news: reverse split" url: "https://aibio.space/companies/ernexa-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ERNA reverse split news: Ernexa Therapeutics gets Nasdaq minimum bid price notice, plans to request hearing. Ernexa Therapeutics Inc." --- ERNA Ernexa Therapeutics Inc. NASDAQ · United States # Ernexa Therapeutics (ERNA) news ERNA reverse split news Listings · 2026-03-20 ## [Ernexa Therapeutics gets Nasdaq minimum bid price notice, plans to request hearing](https://aibio.space/news/ernexa-therapeutics-gets-nasdaq-minimum-bid-price-notice-plans-request/) Nasdaq staff says Ernexa's stock failed to maintain a $1.00 minimum bid price for 30 consecutive business days, and that the company is not eligible for a 180-calendar day compliance period because of a reverse stock split in the past year. The company plans to request a hearing. ## Latest Ernexa Therapeutics news 1. 2025-03-12 Financings [Eterna Therapeutics (now Ernexa Therapeutics) issues $1,500,000 note to Charles Cherington](https://aibio.space/news/eterna-therapeutics-now-ernexa-therapeutics-issues-1-500-000-note/) Eterna Therapeutics (now Ernexa Therapeutics, Nasdaq: ERNA) received $1,500,000 on March 11, 2025, under a promissory note with 5.0% interest that matures no later than June 15, 2025. 2. 2024-10-29 Financings [Eterna (now Ernexa) closes $1.1 million placement at $0.75 after stockholder vote](https://aibio.space/news/eterna-now-ernexa-closes-1-1-million-placement-0-75-after-stockholder/) Stockholders approved the share issuances at the annual meeting on October 29, 2024, the same day the placement closed. The company also agreed to register the new shares for resale, and its equity had been below Nasdaq's $2.5 million minimum. ## Ernexa Therapeutics at a glance - **Ticker**: ERNA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $5.0 million ### Related companies - [Royalty Pharma](https://aibio.space/companies/royalty-pharma/) NASDAQ: RPRX - [ONCOVISTA INNOVATIVE THERAPIES INC](https://aibio.space/companies/oncovista-innovative-therapies/) OTC: OVIT - [Cocrystal Pharma](https://aibio.space/companies/cocrystal-pharma/) NASDAQ: COCP - [Annexon](https://aibio.space/companies/annexon/) NASDAQ: ANNX - [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) AMEX: PTHS - [Veradermics](https://aibio.space/companies/veradermics/) NYSE: MANE - [Supernus Pharmaceuticals](https://aibio.space/companies/supernus-pharmaceuticals/) NASDAQ: SUPN - [Madrigal Pharmaceuticals](https://aibio.space/companies/madrigal-pharmaceuticals/) NASDAQ: MDGL ### Also on NASDAQ - [Eledon Pharmaceuticals](https://aibio.space/companies/eledon-pharmaceuticals/) ELDN - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) MGRX - [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) SANA - [Zura Bio](https://aibio.space/companies/zura-bio/) ZURA - [Prime Medicine](https://aibio.space/companies/prime-medicine/) PRME - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) SLDB ## What Ernexa Therapeutics does Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are mesenchymal stem cells derived from induced pluripotent stem cells. Its lead product candidate, ERNA-101, is an allogeneic iMSC therapy that secretes IL-7 and IL-15, with an initial focus on platinum-resistant ovarian cancer. In a preclinical study with the University of Texas MD Anderson Cancer Center, ERNA-101 reduced tumor growth and showed a statistically significant survival advantage compared with the control group in an ovarian cancer model. After a successful pre-IND meeting with the FDA in the fourth quarter of 2025, the company expects to complete IND-enabling studies and submit an IND in 2026, and to enter a Phase I investigator sponsored trial in the second half of 2026. The company is also investigating ERNA-201, an IL-10 secreting iMSC, in autoimmune disorders such as rheumatoid arthritis. Its technology is in-licensed from Factor Bioscience Limited under an exclusive license in the fields of cancer, autoimmune disorders and rare diseases. The company is seeking strategic partnerships and research grants. | Product or program | What it is | Stage | |---|---|---| | ERNA-101 | Allogeneic IL-7 and IL-15-secreting iMSCs for platinum-resistant ovarian cancer | Preclinical; IND submission expected in 2026 | | ERNA-201 | IL-10-secreting iMSCs for autoimmune disorders such as rheumatoid arthritis | Under investigation | Summarised from the company's [10-K filed Mar 13, 2026](https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm). ## Ernexa Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$582,000](https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/) | | Net income (loss) | [-$14.1 million](https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/) | [-$44.5 million](https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/) | | Cash from operations | [-$7.0 million](https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/) | [-$15.8 million](https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/) | | Cash and equivalents | [$1.9 million](https://www.sec.gov/Archives/edgar/data/748592/000149315226036424/) | [$1.7 million](https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Ernexa Therapeutics Did Ernexa Therapeutics do a reverse stock split? Our latest story on this, dated Mar 20, 2026: "Ernexa Therapeutics gets Nasdaq minimum bid price notice, plans to request hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ernexa-therapeutics-gets-nasdaq-minimum-bid-price-notice-plans-request/). What is the ticker symbol of Ernexa Therapeutics? Ernexa Therapeutics Inc. trades under the ticker ERNA on NASDAQ. Where is Ernexa Therapeutics listed? Ernexa Therapeutics Inc. is listed on NASDAQ. What is the SEC CIK of Ernexa Therapeutics? The SEC Central Index Key (CIK) for Ernexa Therapeutics Inc. is 748592. Its filings are on SEC EDGAR. How many shares does Ernexa Therapeutics have outstanding? 1,632,411 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Ernexa Therapeutics listed under? Our directory records Ernexa Therapeutics Inc. under United States. What does Ernexa Therapeutics do? Our directory classifies Ernexa Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Ernexa Therapeutics? The ISIN recorded for Ernexa Therapeutics Inc. is US1140824079. Does aibio.space cover Ernexa Therapeutics? aibio.space lists Ernexa Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Ernexa Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Ernexa Therapeutics develop? Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are mesenchymal stem cells derived from induced pluripotent stem cells. Its lead product candidate, ERNA-101, is an allogeneic iMSC therapy that secretes IL-7 and IL-15, with an initial focus on platinum-resistant ovarian cancer. What is ERNA-101 from Ernexa Therapeutics? ERNA-101: Allogeneic IL-7 and IL-15-secreting iMSCs for platinum-resistant ovarian cancer Stage: Preclinical; IND submission expected in 2026. What is ERNA-201 from Ernexa Therapeutics? ERNA-201: IL-10-secreting iMSCs for autoimmune disorders such as rheumatoid arthritis Stage: Under investigation. Is Ernexa Therapeutics profitable? Ernexa Therapeutics Inc. reported a net loss of $14.1 million for the fiscal year ended Dec 31, 2025, and used $7.0 million of cash in operations, per its annual report to the SEC. How much cash does Ernexa Therapeutics have? $5.0 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Ernexa Therapeutics Members talk about Ernexa Therapeutics (ERNA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Ernexa Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-04 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/748592/000149315226021112/form8-k.htm) 2. 2026-03-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/form8-k.htm) 3. 2026-03-16 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/748592/000149315226010128/forms-3.htm) 4. 2026-02-03 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/748592/000149315226004809/forms-1.htm) 5. 2025-07-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/748592/000164117225018009/form8-k.htm) 6. 2025-06-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/748592/000164117225014877/form8-k.htm) 7. 2025-06-09 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/748592/000164117225014318/form8-k.htm) 8. 2025-06-02 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/form8-k.htm) 9. 2025-04-14 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/748592/000164117225004585/formdef14a.htm) 10. 2025-04-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/748592/000164117225002606/formpre14a.htm) 11. 2025-01-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). [Source](https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/form8-k.htm) 12. 2025-01-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ERNA on TradingView](https://www.tradingview.com/symbols/NASDAQ-ERNA/). ## SEC filings and registration - **SEC name**: Ernexa Therapeutics Inc. - **CIK**: 748592 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ERNA (Nasdaq), ERNAW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1035 CAMBRIDGE STREET, CAMBRIDGE, MA, 02141 - **Phone**: (617) 798-6700 - **Shares outstanding**: 1,632,411 as of 2026-08-06 (10-Q filed 2026-08-06) - **Former names**: Eterna Therapeutics Inc.; Brooklyn ImmunoTherapeutics, Inc.; NTN BUZZTIME INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/748592/000149315226047287/form8-k.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/748592/000149315226042963/form8-k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/748592/000149315226042934/form8-k.htm) filed 2026-09-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/748592/000149315226036424/form10-q.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/748592/000149315226031930/form8-k.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/748592/000149315226031920/form8-k.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/748592/000149315226030306/form8-k.htm) filed 2026-06-26 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/748592/000149315226022281/formdef14a.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000748592), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Ernexa Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ERNA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Ernexa Therapeutics Inc. - **Ticker**: ERNA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US1140824079 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ERNA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ernexa-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ernexa Therapeutics (ERNA) news: reverse split", 2026-10-31, https://aibio.space/companies/ernexa-therapeutics/